US Market For Physician-Dispensed Cosmeceuticals Will See Strong Growth Through 2022 This Market Will Continue to Be Dominated by Large Global Competitors with Broad Aesthetics Portfolios, According to Millennium Research Group
TORONTO, Oct. 31, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the US market for physician-dispensed cosmeceuticals will see strong growth, driven by high patient aesthetic consciousness. These products hold lucrative revenue potential and are paid for out-of-pocket by patients, making them attractive to physicians. As a result, more physicians are carrying these products in their practices, which will improve accessibility and awareness among the patient population.
Most revenue growth in this space will stem from sales of physician-dispensed sunscreens and antiaging cosmeceuticals. Clinical data increasingly supports the use of products that protect the skin from the harmful effects of the sun, which can result in dark spots and wrinkles. Antiaging products currently represent the largest segment of the physician-dispensed cosmeceutical market, and therefore competitors will need a strong portfolio of these products if they are to compete successfully in the cosmeceutical space.
Acquisitions are common in the cosmeceutical market, and top companies have each been acquired by larger global aesthetics competitors. SkinCeuticals has been a subsidiary brand of L'Oreal since 2005, and through 2012 and early 2013, Obagi Medical Products was acquired by Valeant Pharmaceuticals while SkinMedica was acquired by Allergan. The acquisitions have granted the subsidiary companies access to greater resources, including networks of sales representatives and extensive funds for marketing and endorsements.
Acquisitions also offer significant opportunity for cross-selling, given that the parent companies offer additional cosmetic or antiaging treatments such as chemical peels, facial injectables and breast implants. Opportunities for cross-selling are further explored in MRG's Physician Forum: From Cosmeceuticals to Invasive Aesthetic Treatments survey report.
Smaller companies will need to differentiate themselves by developing distinctive and effective products; for example, Neocutis' portfolio is unique for the inclusion of human growth factors in its products. Small companies can also target certain niche markets. Topix has successfully implemented this strategy by offering private labeling for physicians.
Millennium Research Group's US Markets for Physician-Dispensed Cosmeceuticals 2014 report includes unit, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for cosmeceutical antiaging products, acne treatments, sun protection products, hydrating moisturizers, chemical peels and preparation cosmeceuticals in the United States.
About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
SOURCE Millennium Research Group